Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
Ho Soo Chun, A Reum Choe, Minjong Lee, Yuri Cho, Hwi Young Kim, Kwon Yoo, Tae Hun Kim
Clin Mol Hepatol. 2021;27(4):535-552.   Published online 2021 Jun 16     DOI: https://doi.org/10.3350/cmh.2021.0109
Citations to this article as recorded by Crossref logo
Analysis of Related Influencing Factors of Portal Vein Thrombosis After Hepatectomy
ShiGuai Qi, Jie Tao, Xinhua Wu, Xu Feng, Guoying Feng, Zhengrong Shi
Journal of Laparoendoscopic & Advanced Surgical Techniques.2024;[Epub]     CrossRef
Portal Vein Variations, Clinical Correlation, and Embryological Explanation: A Review Article
Gareema Tyagi, Roshan K Jha
Cureus.2023;[Epub]     CrossRef
THE SURGEON'S PERSPECTIVE ON PORTAL VEIN THROMBOSIS IN PATIENTS WITH LIVER CIRRHOSIS
S.M. Vasyliuk, V.I. Hudyvok, І.R. Labiak, N.M. Pavliuk, V.M. Atamaniuk
Art of Medicine.2023; : 152.     CrossRef
Heparins for prevention and treatment of venous thromboembolism in cirrhosis: Research advances
Zhe Li, Wen-Tao Xu, Xiang-Bo Xu, Xing-Shun Qi
World Chinese Journal of Digestology.2022; 30(9): 381.     CrossRef
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?
Xiaobing Wang, Liping Chen
Hepatology International.2022; 16(5): 1248.     CrossRef
Direct oral anticoagulants (DOACs): From the laboratory point of view
Sandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, Marija Razum
Acta Pharmaceutica.2022; 72(4): 459.     CrossRef